Julie C.
- Country
- France
- Department
- Dermatology, allergology, photobiology
Research Overview
- A MULTICOHORT, OPEN LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) FOR TREATMENT OF ADVANCED MELANOMA REFRACTORY TO PRIOR CHECKPOINT INHIBITOR THERAPY
- Efficacy and Safety Evaluation of JNJ-77242113 Versus Placebo and Deucravacitinib in Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Controlled Trial
- A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
Data & Insights
Has run more than one trial at 144 of 327 partner sites.
Specializations
Melanoma Research
Specializes in investigating novel therapeutic approaches for advanced and metastatic melanoma, with particular focus on combination immunotherapy strategies.
- Unresectable and metastatic melanoma treatment
- Immunotherapy combinations in melanoma
- Post-surgical melanoma management
Explores innovative treatment pathways for patients with checkpoint inhibitor-refractory melanoma.
Cutaneous Oncology
Focuses on developing treatments for advanced cutaneous squamous cell carcinoma and other skin malignancies.
- Advanced CSCC therapies
- Novel monotherapy approaches
- Combination treatment strategies
Investigates treatments for cases not amenable to conventional surgery or radiotherapy.
Immunotherapy Innovation
Conducts research on immune checkpoint inhibitors and their combinations across various skin cancers.
- Long-term safety evaluations
- Novel immunotherapy combinations
- Pan-tumor applications
Evaluates emerging therapeutic approaches in dermatologic oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.